AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32401189 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization/permutation inference
Number of subjects: 90
Study 35767044 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bioactive pastes containing niobophosphate (NbG) and 45S5 glasses at concentrations of 10%, 20%, or 30%.
Number of subjects: 40
Study 35767044 — intervention group
Group type: COMPARATOR
Intervention: Placebo paste without bioactive glass.
Number of subjects: 40
Study 35767044 — intervention group
Group type: COMPARATOR
Intervention: Commercial paste (Nano P, FGM).
Number of subjects: 40
Study 33797501 — intervention group
Group type: EXPERIMENTAL
Intervention: VTE patients
Number of subjects: 558
Study 33797501 — intervention group
Group type: COMPARATOR
Intervention: Non-VTE patients
Number of subjects: 558
Study 32955967 — intervention group
Group type: EXPERIMENTAL
Intervention: Reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks)
Number of subjects: 45
Study 32955967 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 1% ophthalmic solution (Pred Forte®, 4 times daily taper for 6 weeks)
Number of subjects: 45
Study 32955967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of reproxalap 0.5% ophthalmic solution (4 times daily for 6 weeks) and prednisolone 1% ophthalmic solution (twice daily taper for 6 weeks)
Number of subjects: 45
Study 34958980 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated DBT skills videos for 14 successive days (n = 99)
Number of subjects: 153
Study 34958980 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 54)
Number of subjects: 153
Study 34703529 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2.5 mg/day with methadone (LD group)
Number of subjects: 52
Study 34703529 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg/day with methadone (HD group)
Number of subjects: 52
Study 34703529 — intervention group
Group type: COMPARATOR
Intervention: Placebo with methadone (LD and HD groups)
Number of subjects: 52
Study 35321859 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 213
Study 33225584 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDRp + Treatment as Usual (TAU)
Number of subjects: 60
Study 33225584 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 60
Study 33279827 — intervention group
Group type: EXPERIMENTAL
Intervention: Imitation group
Number of subjects: 0
Study 33279827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overimitation group
Number of subjects: 0
Study 33279827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overimitation video
Number of subjects: 0
Study 33279827 — intervention group
Group type: EXPERIMENTAL
Intervention: Age comparison
Number of subjects: 0
Study 33279827 — intervention group
Group type: COMPARATOR
Intervention: Baseline control groups
Number of subjects: 0
Study 34516666 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin
Number of subjects: 60
Study 34516666 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 60
Study 33788481 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic beads auricular point sticking therapy
Number of subjects: 160
Study 33788481 — intervention group
Group type: COMPARATOR
Intervention: Control group (epidural labor analgesia only)
Number of subjects: 160
Study 36083488 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenshen Jianpi recipe (WJR) combined with antiretroviral therapy (ART)
Number of subjects: 56
Study 36083488 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 56
Study 33409689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 102
Study 33409689 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 102
Study 33409689 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional procedures)
Number of subjects: 102
Study 33839075 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 4796
Study 33839075 — intervention group
Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4796
Study 33126310 — intervention group
Group type: EXPERIMENTAL
Intervention: DA‐5204 (Stillen 2X, 90 mg of Artemisia asiatica 95% ethanol extract per tablet) with pantoprazole 40 mg once daily
Number of subjects: 70
Study 33126310 — intervention group
Group type: COMPARATOR
Intervention: Placebo with pantoprazole 40 mg once daily
Number of subjects: 70
Study 33126310 — intervention group
Group type: EXPERIMENTAL
Intervention: DA‐5204 (Stillen 2X) with pantoprazole 40 mg once daily
Number of subjects: 70
Study 615917012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who watched a video explaining the role of a surgical simulator in resident training (group one)
Number of subjects: 410
Study 615917012 — intervention group
Group type: COMPARATOR
Intervention: Patients who did not watch the video (group two)
Number of subjects: 410
Study 615917012 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 410
Study 35619141 — intervention group
Group type: EXPERIMENTAL
Intervention: AFO with oil damper (AFO-OD)
Number of subjects: 41
Study 35619141 — intervention group
Group type: COMPARATOR
Intervention: Nonarticulated AFO
Number of subjects: 41
Study 34874655 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenosanic acid (Dibufelon)
Number of subjects: 120
Study 34874655 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 35917650 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 600 mg twice a day
Number of subjects: 50
Study 35917650 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 33518298 — intervention group
Group type: COMPARATOR
Intervention: Control diet (corn soy) with 0% WB or SBP
Number of subjects: 540
Study 33518298 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% SBP diet
Number of subjects: 540
Study 33518298 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% SBP diet
Number of subjects: 540
Study 33518298 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% WB diet
Number of subjects: 540
Study 33518298 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylanase supplementation (100 mg per kg)
Number of subjects: 540
Study 35134913 — intervention group
Group type: EXPERIMENTAL
Intervention: Piano training
Number of subjects: 155
Study 35134913 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐assisted cognitive training
Number of subjects: 155
Study 35134913 — intervention group
Group type: COMPARATOR
Intervention: No‐treatment control
Number of subjects: 155
Study 32979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-with-insulin (GwI) infusions
Number of subjects: 132
Study 32979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower pretreatment capillary blood glucose (CBG)
Number of subjects: 132
Study 32979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis of type 2 diabetes
Number of subjects: 132
Study 32979855 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for hyperkalaemia within the previous 24 hours
Number of subjects: 132
Study 33035082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis (low-THC)
Number of subjects: 6
Study 33035082 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (BrAC approximately 0.05%)
Number of subjects: 6
Study 34403424 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based mass drug administration (MDA) with albendazole
Number of subjects: 6153
Study 36094652 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop deep brain stimulation (DBS) therapy
Number of subjects: 4
Study 36094652 — intervention group
Group type: COMPARATOR
Intervention: Conventional deep brain stimulation (DBS)
Number of subjects: 4
Study 36094652 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop deep brain stimulation (DBS)
Number of subjects: 4
Study 34143584 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulk-fill material Admira Fusion x‐tra, applied with increments up to 4 mm
Number of subjects: 30
Study 34143584 — intervention group
Group type: COMPARATOR
Intervention: Regular Admira Fusion, applied by a 2 mm layering technique
Number of subjects: 30
Study 32896776 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume hospitals
Number of subjects: 799
Study 32896776 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon volume
Number of subjects: 799
Study 32896776 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation (CRT)
Number of subjects: 799
Study 35881980 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptations in research design and data collection due to COVID-19 pandemic
Number of subjects: 0
Study 35881980 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional quantitative and qualitative data collection and analysis
Number of subjects: 0
Study 32534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic shunt
Number of subjects: 276
Study 32534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver shunt
Number of subjects: 276
Study 32534645 — intervention group
Group type: COMPARATOR
Intervention: Standard drain
Number of subjects: 276
Study 35830484 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binder (n = 16)
Number of subjects: 34
Study 35830484 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 18)
Number of subjects: 34
Study 32615623 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical services for exclusive remote treatment
Number of subjects: 217
Study 36079092 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait/Trunk Group (GTG) - robotic gait rehabilitation and balance with a robotic platform, 3 times/week for 12 sessions/month
Number of subjects: 36
Study 36079092 — intervention group
Group type: COMPARATOR
Intervention: Gait Group (GG) - robotic treatment for gait rehabilitation through an end-effector system
Number of subjects: 36
Study 33092476 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevalence among transgender women
Number of subjects: 304
Study 33092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 304
Study 33092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Residence in Asunción department
Number of subjects: 304
Study 33092476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use
Number of subjects: 304
Study 35837489 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral triazolam
Number of subjects: 124
Study 35837489 — intervention group
Group type: COMPARATOR
Intervention: IV midazolam
Number of subjects: 124
Study 33403428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml 0.375% ropivacaine at T2, T5, and T8 levels
Number of subjects: 60
Study 35260182 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 Now intervention (agenda-setting tool, interactive messaging system, support worker)
Number of subjects: 57
Study 35260182 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 Now intervention (agenda-setting tool, support worker)
Number of subjects: 57
Study 35260182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study 32586399 — intervention group
Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) Solution for injection 10 μg/ml, administered as 0.8g/kg i.v. bolus followed by 0.113g.kg-1.h-1 i.v. infusion for 48 hours, then a maintenance dose of 0.057g.kg-1.h-1 i.v. until weaning or end of follow-up (max 30 days).
Number of subjects: 60
Study 32586399 — intervention group
Group type: COMPARATOR
Intervention: Placebo with identical composition and dosage apart from the active substance.
Number of subjects: 60
Study 36072908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally 36 h, 24 h, and 12 h before surgery
Number of subjects: 168
Study 36072908 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally at the same time points preoperatively
Number of subjects: 168
Study 36072908 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg orally
Number of subjects: 168
Study 36072908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 32283407 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg yohimbine
Number of subjects: 125
Study 32283407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 35886553 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (otitis, atopic dermatitis, premature delivery)
Number of subjects: 613
Study 33615388 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (TEA)
Number of subjects: 12
Study 33615388 — intervention group
Group type: COMPARATOR
Intervention: Dynamic exercise
Number of subjects: 12
Study 32467347 — intervention group
Group type: EXPERIMENTAL
Intervention: Polygenic score for platelet count (223 SNPs)
Number of subjects: 959
Study 32467347 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve platelet count-associated SNPs
Number of subjects: 959
Study 32467347 — intervention group
Group type: EXPERIMENTAL
Intervention: Three SNPs (rs10058074, rs210142, rs2836441)
Number of subjects: 959
Study 32245308 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg melatonin per day for 24 weeks
Number of subjects: 50
Study 32245308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 34613361 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 33134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants meeting SPRINT eligibility criteria (4,036 participants, 15.5%)
Number of subjects: 26093
Study 33134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants eligible for SPRINT not treated for hypertension (56.2%)
Number of subjects: 26093
Study 33134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants not previously considered to have hypertension (542 participants, 13.4%)
Number of subjects: 26093
Study 33134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with hypertension potentially benefiting from treatment intensification (3,494 participants, 30.0%)
Number of subjects: 26093
Study 33134378 — intervention group
Group type: EXPERIMENTAL
Intervention: Most common antihypertensive medication class being taken
Number of subjects: 26093
Study 35751005 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) with red and infrared LEDs (660 nm and 850 nm), 126 mW power, 75.6 J per point, applied once per day three times per week for 2 weeks.
Number of subjects: 18
Study 35751005 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 18
Study 33021466 — intervention group
Group type: EXPERIMENTAL
Intervention: FTD/TPI
Number of subjects: 251
Study 33021466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 34866254 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visitation program using the Problem-Solving Tools for PPD (PST4PPD) model delivered by master's level social workers
Number of subjects: 118
Study 34866254 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with a psychiatrist
Number of subjects: 118
Study 32170754 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCNet
Number of subjects: 38
Study 32170754 — intervention group
Group type: COMPARATOR
Intervention: DeepMedic
Number of subjects: 38
Study 32170754 — intervention group
Group type: COMPARATOR
Intervention: 3D U-Net
Number of subjects: 38
Study 32170754 — intervention group
Group type: COMPARATOR
Intervention: V-Net
Number of subjects: 38
Study 32170754 — intervention group
Group type: COMPARATOR
Intervention: Dense V-Net
Number of subjects: 38
Study 36094772 — intervention group
Group type: EXPERIMENTAL
Intervention: Fampridine plus intravenous methylprednisolone (IVMP) for 7 days
Number of subjects: 30
Study 36094772 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus intravenous methylprednisolone (IVMP) for 7 days
Number of subjects: 30
Study 33619807 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofiber strain (Eff)
Number of subjects: 30
Study 32217211 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial arch support foot orthoses (FOs)
Number of subjects: 30
Study 32217211 — intervention group
Group type: COMPARATOR
Intervention: Flat 2-mm-thick insole (Control)
Number of subjects: 30
Study 36184068 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks
Number of subjects: 805
Study 36184068 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 every 3 weeks
Number of subjects: 805
Study 33655944 — intervention group
Group type: EXPERIMENTAL
Intervention: MOOC-based blended learning
Number of subjects: 181
Study 33655944 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face classroom teaching
Number of subjects: 181
Study 35739544 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex locomotion therapy (EGrlt)
Number of subjects: 106
Study 35739544 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive mobilizations with gentle joint compression (EGpmc)
Number of subjects: 106
Study 35739544 — intervention group
Group type: COMPARATOR
Intervention: Massage (CG)
Number of subjects: 106
Study 33185181 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG testing using ELISA techniques
Number of subjects: 133
Study 33185181 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 IgG testing
Number of subjects: 133
Study 32919855 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereoscopic display
Number of subjects: 22
Study 32919855 — intervention group
Group type: COMPARATOR
Intervention: Nonstereo display
Number of subjects: 22
Study 34535473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry intervention for identifying hypoxaemia in children with severe pneumonia.
Number of subjects: 0
Study 34535473 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical signs of severe pneumonia (fast breathing and/or chest in-drawing, and one or more danger signs).
Number of subjects: 0
Study 34269453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-titer group O whole-blood (LTOWB)
Number of subjects: 36
Study 34269453 — intervention group
Group type: COMPARATOR
Intervention: Standard blood component transfusion
Number of subjects: 36
Study 32434001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy platelet factor 4 (tertile 3)
Number of subjects: 584
Study 32434001 — intervention group
Group type: COMPARATOR
Intervention: Pre-pregnancy platelet factor 4 (tertile 3) in placebo group
Number of subjects: 584
Study 32434001 — intervention group
Group type: COMPARATOR
Intervention: Pre-pregnancy platelet factor 4 (tertile 3) in aspirin group
Number of subjects: 584
Study 35263518 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (1.1 GBq) after injections of recombinant human thyrotropin
Number of subjects: 730
Study 35263518 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radioiodine
Number of subjects: 730
Study 33180039 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop training (46 students)
Number of subjects: 90
Study 33180039 — intervention group
Group type: COMPARATOR
Intervention: Untrained group (44 students)
Number of subjects: 90
Study 33180039 — intervention group
Group type: EXPERIMENTAL
Intervention: Second assessment of trained participants (n=80)
Number of subjects: 90
Study 36183062 — intervention group
Group type: EXPERIMENTAL
Intervention: Demodex-positive young patients
Number of subjects: 202
Study 36183062 — intervention group
Group type: EXPERIMENTAL
Intervention: Demodex-positive elderly patients
Number of subjects: 202
Study 36183062 — intervention group
Group type: COMPARATOR
Intervention: Elderly Demodex-positive patients vs. young patients
Number of subjects: 202
Study 36183062 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly Demodex-positive patients
Number of subjects: 202
Study 35725624 — intervention group
Group type: EXPERIMENTAL
Intervention: 2GETHER: a relationship education and HIV prevention program, delivered face-to-face in a university setting, composed of two group sessions and two individualized skills coaching sessions.
Number of subjects: 256
Study 35725624 — intervention group
Group type: COMPARATOR
Intervention: Control condition based on a well-validated positive affect enhancement program.
Number of subjects: 256
Study 32020635 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone treatment
Number of subjects: 58
Study 34775577 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg daily for 12 weeks
Number of subjects: 140
Study 34775577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 33260063 — intervention group
Group type: EXPERIMENTAL
Intervention: Criscy™ (biosimilar recombinant growth hormone)
Number of subjects: 81
Study 33260063 — intervention group
Group type: COMPARATOR
Intervention: Genotropin™ (originator recombinant growth hormone)
Number of subjects: 81
Study 32349835 — intervention group
Group type: EXPERIMENTAL
Intervention: RemedRugby (RR)
Number of subjects: 87
Study 32349835 — intervention group
Group type: COMPARATOR
Intervention: Touch Rugby (TR)
Number of subjects: 87
Study 34739197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (initial dose 12.5 mg/day, max 50 mg/day)
Number of subjects: 160
Study 34739197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 34739197 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Number of subjects: 160
Study 32576258 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 6-day treatment with artemether-lumefantrine and a single low-dose primaquine
Number of subjects: 280
Study 32576258 — intervention group
Group type: COMPARATOR
Intervention: Standard 3-day treatment with artemether-lumefantrine (control)
Number of subjects: 280
Study 35997730 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d)
Number of subjects: 9711
Study 35997730 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (40 mg/d)
Number of subjects: 9711
Study 34663636 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 0
Study 34663636 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 0
Study 34663636 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to upadacitinib at week 24)
Number of subjects: 0
Study 34663636 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg
Number of subjects: 0
Study 33380535 — intervention group
Group type: EXPERIMENTAL
Intervention: Fendrix® (t = 0, 4, 8, 24 weeks)
Number of subjects: 48